Video
How to lower medical expenses for patients
Author(s):
“We want to make sure that if it is an efficacious medicine for that patient to consider using a generic formulation,” says Kelvin A. Moses, MD, PhD, FACS.
Video Player is loading.
In this video, Kelvin A. Moses, MD, PhD, FACS, discusses the topics and advice from his presentation, “Financial and toxicity considerations when managing advanced PCa,” presented recently at the 2021 Society of Urologic Oncology Annual Meeting. Moses is an associate professor of urology and fellowship director of urologic oncology at the Vanderbilt University Medical Center in Nashville, Tennessee.
Related Videos
Ruchika Talwar, MD, on how urologists can get involved in advocacy
Ruchika Talwar, MD, discusses ongoing drug shortages in urology
Gopa Iyer, MD, highlights findings from FORAGER-1 in metastatic urothelial carcinoma
William Furuyama, MD, on community factors’ influence on urinary incontinence
Michael Schweizer, MD, shares data on mevrometostat plus enzalutamide in mCRPC
Laura Bukavina, MD, highlights study of urinary microbiome profiling
Kate Gessner, MD, on the mechanisms of immunotherapy failure in RCC
Darren Feldman, MD, on clinical outcomes in R/R testicular germ cell tumors
ASCO GU recap: Insights on 5 key trials
Laurence Albiges, MD, on COSMIC-313 trial of triplet vs doublet combination in aRCC
Related Content
